Most pathological conditions that arise within the human body are the result of underlying biochemical defects, and often the success or failure of subsequent treatment depends upon an early identification of these defects. For this reason, medical diagnostic techniques that reflect biochemical or metabolic behaviour have a special significance. One such technique, positron emission tomography (PET), is based on the radiolabeling of substrates that are involved in the fundamental biochemical processes of the body. External detection and imaging of the radiation emitted by the radiolabel enables the chosen substrate to be monitored as it progresses along a particular metabolic pathway. In as far as the image of the emitted radiation reflects the biochemistry of the substrate in the body, abnormalities of biochemistry may be identified from the image. Thus, apart from the introduction into the body of a small quantity of radioactivity, PET is entirely non -invasive and without undue risk to the patient. To be successful, such an approach will require: the development of suitable instrumentation for imaging the radiation, the development of radiolabels with a well-understood fate within the body, the development of mathematical models that will explain in simple terms the kinetic behaviour of the tracers so as to distinguish pathology from normal function.
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The replacement of stable oxygen O in the body by the positron-emitter O will have no noticeable effect on body biochemistry, but the decay of O may be used to monitor externally the metabolic behaviour of>oxy-13 gen.
Similar examples are the replacement of stable nitrogen by N and stable carbon by C . Each of these isotopes may be administered to the patient in a number of different chemical forms, for example C O carbon monoxide, or 13 N H 3 ammonia.
The positron, after emission from the parent nucleus, rapidly loses energy to the surrounding tissue and eventually annihilates with an electron to give rise to two 511 keV photons that leave the annihilation point 180° apart. The distribution of these annihilation photons is imaged by devices known as positron cameras. They consist of detectors operating in coincidence that localise externally the two photons from an annihilation inside the patient. A line joining these two measured points follows the path of the photons and passes through, or close to, the annihilation point, which in turn is close to the position of the nucleus that originally emitted the positron. Although the actual position of the annihilation point on the line is, of course, unknown, the total number of photon pairs detected for this line during the time of imaging will, after correction for scatter and attenuation, be proportional to the sum of the radioisotope activity on or close to the line. By placing detector pairs in a ring around the patient, many such 'line integrals' may be measured for a single two -dimensional cross -section. Mathematical techniques similar to those used in X -ray computed tomography may be used to reconstruct the two -dimensional section from the line integrals of activity, and thus map the distribution of the radiolabeled tracer throughout the section.
Such single section devices, however, make inefficient use of the emitted photons since the detector ring covers only a small solid angle. This situation may be improved by adding extra rings of detectors, but the increase in cost is often considerable. Alternatively, two -dimensional area detectors offer direct multi -slice (volume) imaging at a more economic cost, but this advantage is frequently offset by low efficiency and sensitivity to scatter that limit their application. Over the past few years, major technological effort at a number of research centres has been concentrated on the design and construction of positron cameras of high spatial resolution, high imaging sensitivity and multi -slice capability. The original sodium iodide detectors have been replaced by bismuth germinate and, more recently, fast scintillators such as cesium fluoride and barium fluoride. The latter detectors offer the possibility of measuring, to a precision of a few hundred picoseconds, the time difference for the arrival of the two annihilation photons. Such a precision corresponds to a spatial uncertainty of several centimetres and thus the time -of-flight information cannot be used to precisely locate the annihilation point. Instead, the additional information improves the signal to noise in the image and enables cross -plane photon lines to be used in multi -slice systems. Fast coincidence timing also helps to reduce random coincidences, and energy resolution aids in the rejection of scattered coin- Instead, the additional information improves the signal to noise in the image and enables cross-plane photon lines to be used in multi-slice systems. Fast coincidence timing also helps to reduce random coincidences, and energy resolution aids in the rejection of scattered coin-cidences. Current commercial systems for brain imaging, for example, achieve a spatial resolution of about 5 to 6 mm and multisection sensitivities of about 105 cps/pCi/cc for a standard cylindrical phantom of diameter 20 cm.
The developments in instrumentation and data reconstruction have been paralleled by progress in the area of radioactive labelling. The most interesting positron-emitters have short half -lives, however, requiring a cyclotron for their production within close proximity to the positron camera. Inevitably, this limits the widespread application of positron tomography, although PET systems are currently found at some 40 centres worldwide, not all of which have access to an in -house cyclotron. Alternatives to cyclotron-produced, short -lived radioisotopes include F18 with a 110 minute half -life that allows time for the transportation from the cyclotron to the camera providing the distance is not too great, Ga68 which may be eluted from a Ge68 generator, Rb82 also from a generator, and 1124 and Co55 which are cyclotron -produced but have longer half -lives of 4.2 days and 17.5 hours respectively.
For the purposes of diagnostic functional imaging, positron emitters may be used as natural substrates, or to label substrate analogues, pharmaceuticals, neurotransmitters and more recently, antibodies, cells and proteins. Examples of well -known positron imaging applications include the use of 0150 for cerebral oxygen metabolism studies, 015-labelled water for cerebral blood flow, F18 -2-deoxyglucose for glucose metabolism studies in the brain and heart, C11-palmitate for fatty acid metabolism in the heart, Co55-bleomycin for tumour localisation, 1124 for thyroid metabolism and F18 6-fluoro -L -dopa for the investigation of the intracerebral dopaminergic pathways. The range of actual and potential applications is extremely wide.
Tracer distributions determined by positron tomography are qualitative images that reflect the functional behaviour of the particular organ that accumulates the tracer. Pathological effects show up as regions of abnormally increased or decreased uptake as a consequence of disturbed local metabolism. inspection of the image to small metabolic changes, leading to an earlier detection of physiologic defects. The combination of quantitative data with mathematical models describing tracer kinetics should give a greater insight into the underlying physiology both in health and disease.
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